Aurora kinase A drives the evolution of resistance to third generation EGFR inhibitors in lung cancer

Although targeted therapies often elicit profound initial patient responses, these effects are transient due to residual disease leading to acquired resistance. How tumors transition between drug responsiveness, tolerance and resistance, especially in the absence of pre-existing subclones, remains u...

Descripción completa

Detalles Bibliográficos
Autores principales: Shah, Khyati N., Bhatt, Roma, Rotow, Julia, Rohrberg, Julia, Olivas, Victor, Wang, Victoria E., Hemmati, Golzar, Martins, Maria M., Maynard, Ashley, Kuhn, Jonathan, Galeas, Jacqueline, Donnella, Hayley J., Kaushik, Swati, Ku, Angel, Dumont, Sophie, Krings, Gregor, Haringsma, Henry J., Robillard, Liliane, Simmons, Andrew D., Harding, Thomas C., McCormick, Frank, Goga, Andrei, Blakely, Collin M., Bivona, Trever G., Bandyopadhyay, Sourav
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6324945/
https://www.ncbi.nlm.nih.gov/pubmed/30478424
http://dx.doi.org/10.1038/s41591-018-0264-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6324945/
https://www.ncbi.nlm.nih.gov/pubmed/30478424
http://dx.doi.org/10.1038/s41591-018-0264-7

Ejemplares similares